tuftsin is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-06-10. Numbers and descriptions here follow the published literature rather than marketing material.
Reported activity for Selank centers on anxiolytic and nootropic effects. Russian clinical reports describe use in anxiety and in cognitive or attention-related complaints. Most of this evidence comes from studies conducted by the same research groups that developed the peptide. Independent replication in other countries remains limited, and no major Western regulatory agency has approved the compound for any indication. The gap between local reports and external verification is a recurring point in discussions of the peptide.
Tuftsin, the parent structure, is a naturally occurring immunomodulatory tetrapeptide released from the Fc region of immunoglobulin G by spleen enzymes. Selank extends this four-residue sequence with three additional amino acids. The stated rationale is that the added tail slows enzymatic breakdown and may influence receptor interactions. How the full heptapeptide behaves at the molecular level is not firmly established, and proposed mechanisms often involve indirect modulation of neurotransmitter or immune signaling rather than a single defined target.
Selank is a synthetic heptapeptide developed in Russia. Its sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro, a seven-residue chain built around the natural tetrapeptide tuftsin. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences first described the compound in the mid-1990s. The design combined the tuftsin core with an added Pro-Gly-Pro tail, a modification intended to extend the molecule's stability in biological fluids. Published work on the peptide has appeared mainly in Russian-language journals.
Reported pharmacological effects center on reduced anxiety-like behavior in animal models and on measures of memory and learning. Proposed contributing mechanisms include modulation of GABAergic signaling, shifts in monoamine turnover, and changes in the activity of enzymes that degrade neuropeptides. Effects on the expression of genes linked to neuroplasticity have also been described. No single molecular target is widely accepted, and whether the behavioral findings arise from one pathway or several remains an open question.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It was designed as a stabilized analogue of tuftsin, a naturally occurring tetrapeptide fragment derived from the immunoglobulin heavy chain. The additional Pro-Gly-Pro segment at the carboxyl terminus is intended to slow enzymatic cleavage. The compound is usually described in the literature as a synthetic peptide with anxiolytic and cognitive-related activity, a label that reflects a research context rather than an approved therapeutic category.
Most published work on selank originates from a small number of research groups in the Russian Federation. A large share of that record appears in Russian-language journals, which limits access for readers who rely on English-indexed databases. Independent replication by laboratories outside the original research network is sparse in publicly available sources. This concentration of origin and language is a frequently noted feature when the compound is summarized in broader reviews of synthetic peptides.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic heptapeptide | Modeled on tuftsin |
| Amino acid sequence | Thr-Lys-Pro-Arg-Pro-Gly-Pro | Seven residues |
| Approximate molecular mass | Around 750 Da | Depends on counter-ion and hydration |
| Common forms | Lyophilized powder | Also described as aqueous solution |
| Primary origin of research | Russian laboratories | Mid-1990s onward |
The compound was designed at the Institute of Molecular Genetics of the Russian Academy of Sciences during the 1980s and 1990s. The stated design goal was to retain the immunomodulatory and central nervous system activity attributed to tuftsin while improving resistance to enzymatic breakdown. Adding a proline-rich tail to the short parent peptide was a deliberate strategy, because proline residues restrict the conformations available to many peptidases. The same laboratory produced Semax, an ACTH fragment analog, and both compounds were developed in parallel as short, enzymatically stabilized peptides intended for intranasal use.
Selank is not a naturally occurring peptide and has no known endogenous counterpart in human physiology. Russian-language sources frequently call it TP-7, while English-language sources use the name Selank almost exclusively. Database indexing is uneven, partly because early reports appeared in regional journals that are not widely cataloged. Some summaries describe the material as a tuftsin analog and others as a synthetic heptapeptide; the labels overlap rather than conflict. Citing the primary sequence resolves ambiguity more reliably than the research or trade name alone.
Peptide bonds are vulnerable to protease attack, and Selank is no exception. Measured half-life in serum is short, on the order of minutes in several reports, which explains why intranasal administration is the common route described in the literature. Absorption across the nasal mucosa partially bypasses first-pass hepatic metabolism. Quantitative data on human bioavailability remain limited and are difficult to compare across studies.
Lyophilised material kept dry at minus 20 degrees Celsius or colder is the most stable form, and suppliers commonly state a shelf life of two years or more under those conditions. Once dissolved, degradation accelerates through hydrolysis and deamidation, particularly at alkaline pH or elevated temperature. Working solutions are usually divided into single-use aliquots to avoid repeated freeze-thaw cycles. The choice of reconstitution solvent affects both stability and the ionic strength of the final preparation.
Selank is a synthetic heptapeptide developed in Russia during the 1990s. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences designed it as a stabilized analog of tuftsin, a naturally occurring immunomodulatory tetrapeptide. The compound has been studied primarily for its reported anxiolytic and nootropic effects. It remains largely unknown in Western pharmacology and is not approved as a medicine by major regulators such as the FDA or the EMA.
The primary structure of Selank is Thr-Lys-Pro-Arg-Pro-Gly-Pro, corresponding to the molecular formula C33H57N11O9 and a monoisotopic mass of roughly 751.9 daltons. The N-terminal threonine and the arginine residue in the fourth position are shared with tuftsin, which carries the sequence Thr-Lys-Pro-Arg. The three additional residues at the C-terminus, Pro-Gly-Pro, extend the chain and are associated with greater resistance to enzymatic degradation. This extension also separates Selank from the shorter parent peptide.
Naming conventions place Selank in the same research family as Semax, another Russian-developed peptide investigated for cognitive effects. The two compounds share a lineage but differ in sequence and in the biological systems proposed as their targets. Semax descends from ACTH fragments, whereas Selank descends from tuftsin. Publications sometimes identify Selank by its full peptide sequence or by laboratory codes rather than one uniform trade name. Because replication outside Russia is limited, reports on its properties are best read alongside the study design and the purity of the material tested.
=== Regulation by CRISPRi === Recent genome-wide CRISPR interference (CRISPRi) screens have identified genes whose selective inhibition modulates specific components of the SASP during inflammation-induced senescence, such as that triggered by interleukin-6 (IL-6). These approaches have helped distinguish molecular regulators of replicative senescence from those involved in inflammatory senescence, providing new targets for studying aging-related pathways. SASP has been reduced through inhibition of p38 mitogen-activated protein kinases and janus kinase. The protein hnRNP A1 (heterogeneous nuclear ribonucleoprotein A1) antagonizes cellular senescence and induction of the SASP by stabilizing Oct-4 and sirtuin 1 mRNAs.
== Presentation == The most characteristic symptom of acrogeria is thin, atrophic skin with mottled pigmentation and telangiectasia, most severe in the limbs and extremities. This is accompanied by easy bruising, hyperkeratosis, and a loss of subcutaneous fat, which is replaced by connective tissue. Patients have a facies with a pinched face, hollow cheeks, prominent eyes without exophthalmos, a beak-like nose and thin lips. Though the hair and nails are normal in many cases, alopecia and nail dystrophies, such as onychogryphosis and koilonychia, have been reported. Stature is short in some patients and normal in others. The general skeletal structure is unremarkable, but acrogeria results in delayed closure of the cranial sutures, notching of the mandible, and micrognathia; and may also coincide with spina bifida, clubfoot and congenital dislocation of the hips. Sexual development, including the development of secondary sex characteristics, is normal, and so is intelligence. There is no correlation of acrogeria with metabolic, opthamological or cardiovascular disorders, and patients have a normal life expectancy. Similarities between the clinical features of acrogeria and Werner's syndrome have been observed.
In the late 1970s and, particularly, during the early 1980s under U.S. President Ronald Reagan, the United States renewed its commitment to a more powerful military, which required a large increase in spending on U.S. military programs. These programs, which were originally part of the defense budget of U.S. President Jimmy Carter, included spending on conventional and nuclear weapons systems. Under Reagan, defensive systems like the Strategic Defense Initiative were emphasized as well. Another major shift in nuclear doctrine was the development and the improvement of the submarine-launched, nuclear-armed, ballistic missile, or SLBM. It was hailed by many military theorists as a weapon that would make nuclear war less likely. SLBMs—which can move with "stealth" (greatly lessened detectability) virtually anywhere in the world—give a nation a "second strike" capability (i.e., after absorbing a "first strike"). Before the advent of the SLBM, thinkers feared that a nation might be tempted to initiate a first strike if it felt confident that such a strike would incapacitate the nuclear arsenal of its enemy, making retaliation impossible. With the advent of SLBMs, no nation could be certain that a first strike would incapacitate its enemy's entire nuclear arsenal. To the contrary, it would have to fear a near-certain retaliatory second strike from SLBMs. Thus, a first strike was a much less feasible (or desirable) option, and a deliberately initiated nuclear war was thought to be less likely to start.
== Clinical significance == A disease of the entheses is known as an enthesopathy or enthesitis. Enthetic degeneration is characteristic of spondyloarthropathy and other pathologies. The enthesis is the primary site of disease in ankylosing spondylitis.
The citric acid cycle is regulated mainly by the availability of key substrates, particularly the ratio of NAD+ to NADH and the concentrations of calcium, inorganic phosphate, ATP, ADP, and AMP. Citrate – the ion that gives its name to the cycle – is a feedback inhibitor of citrate synthase and also inhibits PFK, providing a direct link between the regulation of the citric acid cycle and glycolysis.
Sources: en.wikipedia.org
Receptors bind with endogenous ligands to produce a physiological effect and regulate the body and cellular homeostasis. In a ligand-receptor interaction, the ligand binds with the receptors to form a drug-receptor complex, producing a biological response. The biological nature of receptors can be enzymes, nucleic acids or cellular proteins. Common types of receptors include G-protein coupled receptors, nuclear receptors and ion channels. Functional antagonists would not produce a biological response after binding with a receptor. It blocks the binding of endogenous ligands to the receptors and thus inhibits the subsequent physiological effect.
12(S)-HpETE and 12(S)-HETE induce itching responses when injected into the skin of mice; this has led to the suggestion that these metabolites contribute to the itching (i.e. clinical pruritus) which accompanies such conditions as atopic dermatitis, contact dermatitis, urticaria, chronic renal failure, and cholestasis. Since it mediates 12(S)-HETE-induced itching in the mouse model, BLT2 rather than GPR31 may mediate human itch in these reactions.
The use of RdRp plays a major role in RNA interference in eukaryotes, a process used to silence gene expression via small interfering RNAs (siRNAs) binding to mRNA rendering them inactive. Eukaryotic RdRp becomes active in the presence of dsRNA, and is less widely distributed than other RNAi components as it lost in some animals, though still found in C. elegans, P. tetraurelia, and plants. This presence of dsRNA triggers the activation of RdRp and RNAi processes by priming the initiation of RNA transcription through the introduction of siRNAs. In C. elegans, siRNAs are integrated into the RNA-induced silencing complex, RISC, which works alongside mRNAs targeted for interference to recruit more RdRps to synthesize more secondary siRNAs and repress gene expression. Spiegelman's Monster NS5B inhibitor RNA+Replicase at the U.S. National Library of Medicine Medical Subject Headings (MeSH) EC 2.7.7.48
60. Vopr Onkol. 2001;47(5):601-7. [Effect of vilon and epithalone on induction and growth of induced bladder neoplasms in rats]. [Article in Russian] Pliss GB(1), Mel'nikov AS, Malinin VV, Khavinson VKh. Author information: (1)N.N. Petrov Research Institute of Oncology, Ministry of Health of the RF, St. Petersburg. Experimental data on the effect of peptides--Vilon (Lys-Glu) and Epitalon (Ala-Glu-Asp-Gly)--on induction of urinary bladder tumors in rats are presented. Treatment with Vilon was followed by a significant fall in tumor incidence in 56% of experimental animals, as compared with 75.5% in control, as well as inhibition of early-onset neoplastic changes in the bladder mucosa. No inhibitory effect of Epitalon was recorded.
Sources: en.wikipedia.org
Orthorhombic AmCl2: a = 896.3±0.8 pm, b = 757.3±0.8 pm and c = 453.2±0.6 pm Tetragonal AmBr2: a = 1159.2±0.4 pm and c = 712.1±0.3 pm. They can also be prepared by reacting metallic americium with an appropriate mercury halide HgX2, where X = Cl, Br or I:
Hypotension (low blood pressure) Dysphoria Tachycardia Malaise Psychomotor impairment It is not believed to be addictive but is known to produce mild withdrawal effects (e.g., anorexia) after abrupt discontinuation.
(2026) determine the distribution of habitats suitable for Neanderthals and modern humans in Europe during stadial and interstadial events of Marine Isotope Stage 3, providing evidence of a shift but not complete disappearance of habitats suitable for Neanderthals as a result of climate changes, weak connectivity between optimal regions for Neanderthals, and overlaps between optimal regions of the two hominins. A Neanderthal infant assigned to the 6- to 14-month age range, providing evidence of rapid somatic growth in early life of Neanderthals, is described from the Amud Cave (Israel) by Been et al. (2026). Blinkhorn et al. (2026) study the variability of Levallois blanks from northeast Africa and southwest Asia, and interpret Levallois stone tools from northern Arabia dating to early Marine Isotope Stage 3 as likely produced by Neanderthals. Evidence from the study of palynological assemblages from the Axlor site (Spain), indicative of marked shifts in landscape structure at the time of the Neanderthal occupation of the site, is presented by Pérez-Díaz et al. (2026). Evidence of short-term Neanderthal occupations of the Eirós cave (Spain), indicative of high mobility of late Neanderthal communities from northwestern Iberian Peninsula, is presented by Rodríguez-Álvarez et al. (2026). Fotiadou et al.
Sources: en.wikipedia.org
Selank is a synthetic peptide made of seven amino acids. It is modeled on tuftsin, a natural tetrapeptide, with an added three-residue tail. It is not a small-molecule drug.
It originates from research in Russia, associated with the Institute of Molecular Genetics of the Russian Academy of Sciences. The first descriptions date to the mid-1990s. Most published studies come from Russian laboratories.
No, Selank itself does not occur naturally. Its backbone is based on tuftsin, which is produced in the body, but the seven-residue version is a synthetic construct. It is supplied as a manufactured peptide.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, designed as a metabolically stabilized analogue of the endogenous tetrapeptide tuftsin. It has been studied mainly against anxiety-related and cognitive endpoints rather than as an approved medicine in most jurisdictions.